Trial of Outpatient Immunotherapy With Rituximab and Aldesleukin (IL-2) vs. Rituximab Alone for Non-Hodgkin's Lymphoma
Status:
Terminated
Trial end date:
2007-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to find out if treatment with rituximab in combination
with aldesleukin (compared to rituximab alone) decreases the risk of cancer returning, as
well as determining what other effects (good and bad) this drug combination has on NHL.
Rituximab and aldesleukin are not approved in combination by the Food and Drug Administration
(FDA) for the treatment of non-Hodgkins lymphoma; however, Rituximab is approved for use by
itself to treat NHL.
Phase:
Phase 2
Details
Lead Sponsor:
US Oncology Research
Collaborators:
Chiron Corporation Fred Hutchinson Cancer Research Center